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LETTERS TO THE EDITOR
To the Editor:
We read with interest the article of Ward and col­
leagues who measured serially circulating interleu- 
kin-2 receptor (sIL2R) levels in rheumatoid arthritis 
(RA) (1). The authors found no significant partial cor­
relations between changes in sIL2R concentrations (as­
sessed every 2 weeks for up to 60 weeks in 24 patients 
with RA) and changes in seven other measures of dis­
ease activity. Those consisted of tender and swollen 
joint count, physician and patient global assessment, 
patient pain score, Health Assessment Questionnaire 
Disability Index, and the erythrocyte sedimentation 
rate and were, with one exception, considered the most 
accurate measures of disease activity in a previous 
study (2). In view of the lack of correlations the authors 
suggest that RA exacerbations are either not accompa­
nied by T cell activation or that the latter is not re­
flected by changes in sIL2R levels.
The role of the T cells in the pathogenesis of RA is 
still unclear but they are likely involved in early 
phases of the disease. Chronic synovitis and its exac­
erbations, however, may be sustained by other cells 
such as macrophages and synovial cells (3).
Herein we would like to comment on some aspects of 
the study by Ward et al. (1). Previous reports have 
uniformly shown that sIL2R concentrations are ele­
vated in patients with active RA and other autoim­
mune diseases and this is considered to reflect activa­
tion of the immune system, especially the T cells (4-6). 
Decreases in sIL2R levels have been observed during 
treatment with corticosteroids (7-9), methotrexate 
(10-12), cyclosporin (13-14), and amiprilose HC1 
(Therafectin) (6) but not with intramuscular gold (8, 
15), oral gold, sulfasalazine (15), azathioprine (10, 16), 
or NSAIDs (17). Despite the different design and fol­
low-up times of these studies, their results suggest that 
antirheumatic drugs differ in their effects on immune 
activation as represented by sIL2R levels. In their 
study, Ward et al. (1) did not prescribe a standard 
treatment. Though the regression models used by the 
authors may have adjusted for initial therapy, treat­
ment was changed in 15 patients (65%) during the 
study. This may have introduced bias due to switching 
from one second-line drug to another in = 7), increasing 
the dosage (n = 5), and prescription of additional an­
tirheumatic drugs (n = 3) (2).
In patients with active RA, decreases in circulating 
sIL2R levels whether significant (6, 10, 18) or not (11, 
17) have been reported to coincide or precede (7, 19)
clinical improvement. Ward et al. (1) used a broad def­
inition of active RA based exclusively on the presence 
of at least six swollen or tender joints and not in other 
usually required additional measures of disease activ­
ity, such as an elevated erythrocyte sedimentation rate 
(ESR) or morning stiffness. The study included pa­
tients with “mildly or moderately” active arthritis (2) 
but there was no clear definition of disease exacerba­
tion or improvement. The authors showed that changes 
in SIL2R levels did not occur simultaneously (or within 
2 to 4 weeks) with other, mostly clinical, parameters of 
disease activity but did not examine the correlations 
with an outcome (either clinical or radiological) after a 
longer follow-up.
In light of previous studies showing only moderate 
(7, 18-21) or absent (3, 10, 11, 15, 22) correlations be­
tween sIL2R and clinical parameters of disease activ­
ity, the results reported by Ward et al. are not surpris­
ing. However several laboratory measurements includ­
ing C reactive protein, ESR (6, 7,10, 11, 15, 16, 19, 21) 
anemia (23), platelet counts (7), interleukin-6, soluble 
tumor necrosis factor receptors (10), and granulocyte- 
macrophage colony stimulating factor (24) have been 
reported to correlate with sIL2R levels and most of 
these were not examined by Ward et al. (1).
We propose that the role of measuring sIL2R levels 
in the short and long-term management of RA should 
be clarified in further longitudinal studies which in­
clude a clear definition of disease activity, avoid 
changes in antirheumatic therapy, and, whenever pos­
sible, standardize for other factors which may influ­
ence sIL2R measurements such as disease duration, 
stress, mood disturbances (20), and the circadian 
rhythm (25).
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REPLY
To the Editor:
Dr. Barrera raises several interesting questions re­
garding our longitudinal study of the relationship be­
tween serum interleukin-2 receptor (sIL-2R) levels and 
arthritis activity in patients with rheumatoid arthritis 
(1). One concern is whether changes in drug treatment 
over time might have been responsible for the limited 
associations we found between changes in sIL-2R lev­
els and arthritis activity. While different medications 
may affect sIL-2R levels to different degrees, a uniform
treatment protocol, either within or among patients, is 
not necessary to examine the concordance of changes in 
different measures of arthritis activity. The phenome­
non under study is the degree to which temporal 
changes in sIL-2R levels correlate with changes in 
other measures of arthritis activity. The direction of 
the change (either clinical improvement or worsening) 
and the cause of the change in clinical status (either 
natural fluctuation in arthritis activity or start of a 
new medication) are not important modifying factors in
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this analysis. If a change in the state of T cell activa­
tion is a prominent factor mediating clinical arthritis 
activity, and if all sIL-2R levels accurately reflect this 
underlying state of T cell activation, then changes in 
sIL-2R levels should reflect changes in arthritis activ­
ity. Treatment with a very effective medication may 
improve clinical arthritis activity greatly, but should 
similarly decrease sIL-2R levels. The clinical improve­
ments resulting from treatment with a less effective 
medication should be associated with less substantial 
decreases in sIL-2R levels. It is the association between 
changes in clinical arthritis activity and sIL-2R levels 
that we assessed.
Because the opportunity to examine relationships 
between different measures of arthritis activity is 
greatest among patients with active arthritis, we re­
stricted study entry to such patients. Over the course of 
observation, we did not categorize patients as either 
improved or worsened, because such definitions would 
have necessarily been arbitrary. In addition, any cate­
gorization of continuous variables, such as joint count 
measures, global assessments, and sedimentation 
rates, would decrease the statistical power of any as­
sociations that might be drawn between sIL-2R levels 
and clinical measures. Appreciation of the relationship 
between short-term changes in clinical arthritis activ­
ity and sIL-2R levels may be gained from our Fig. 1(1). 
For the physician and patient global assessments rep­
resented in this figure, readers may determine their 
own definition of “flare.” Marked worsening of arthri­
tis, as judged by either the examining physician or the 
patient, was often not associated with increases in sIL- 
2R levels. In some cases, large decreases in sIL-2R lev­
els were measured during these time periods.
The arthritis activity measure we used were primar­
ily clinical measures. However, the correlation of sIL-
2R level and the sedimentation rate (partial correla­
tion = -0.12) was no better than those of the clinical 
measures. Correlations between changes in sIL-2R 
level and the hemoglobin level (partial correlation = 
-0.11; P = 0.85) and the platelet count (partial corre­
lation = 0.04; P = 0.31) were also not significant. We did 
not examine other laboratory measures.
The absence of a temporal association between 
changes in sIL-2R levels and a number of clinical and 
laboratory measures of arthritis activity, and the poor 
sensitivity to change of sIL-2R levels over short periods 
of time, suggests that sIL-2R is not a useful evaluative 
measure in rheumatoid arthritis. Longitudinal study 
of several different measures of T cell activation will 
help clarify whether the discordance between arthritis 
activity and sIL-2R levels noted in this study is due to 
the limited role of T cells in mediating clinical exacer­
bations or to the limitations of serum measurements of 
this particular marker of T cell activation.
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